Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives Consensus Rating of “Reduce” from Analysts

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has received a consensus rating of “Reduce” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating and three have assigned a hold rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $28.00.

FMS has been the subject of several research reports. Weiss Ratings downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 5th. UBS Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research note on Wednesday, October 15th. Zacks Research lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Bank of America downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research note on Wednesday, October 15th. Finally, Truist Financial set a $28.00 price objective on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in FMS. US Bancorp DE increased its stake in Fresenius Medical Care AG & Co. KGaA by 225.5% in the 2nd quarter. US Bancorp DE now owns 75,660 shares of the company’s stock valued at $2,162,000 after buying an additional 52,418 shares during the last quarter. ABC Arbitrage SA grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 18.2% in the second quarter. ABC Arbitrage SA now owns 229,375 shares of the company’s stock valued at $6,553,000 after acquiring an additional 35,314 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 26.8% during the second quarter. Envestnet Asset Management Inc. now owns 373,961 shares of the company’s stock valued at $10,684,000 after acquiring an additional 78,956 shares during the last quarter. TD Private Client Wealth LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 6,380.3% during the second quarter. TD Private Client Wealth LLC now owns 4,925 shares of the company’s stock valued at $141,000 after acquiring an additional 4,849 shares during the last quarter. Finally, Trustmark Bank Trust Department bought a new stake in Fresenius Medical Care AG & Co. KGaA during the second quarter worth $1,027,000. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Stock Up 1.7%

NYSE:FMS opened at $22.00 on Friday. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $21.02 and a twelve month high of $30.46. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 0.45. The stock’s 50-day simple moving average is $23.42 and its 200 day simple moving average is $25.10.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its earnings results on Tuesday, November 4th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.05. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.72% and a return on equity of 7.42%. The firm had revenue of $5.73 billion during the quarter, compared to analysts’ expectations of $4.72 billion. Equities analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.